Oragenics (OGEN) director granted 125,000 options at $0.93 exercise price

Rhea-AI Filing Summary

Oragenics director Alan Dunton reported receiving an award of 125,000 options to buy the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.

The options were granted under the company’s 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. They vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this grant, 125,000 derivative securities are beneficially owned directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUNTON ALAN W

(Last) (First) (Middle)

1990 MAIN STREET, SUITE 750

(Street)

SARASOTA FL 34236

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Employee Director Option (Right to Buy)(1)	$0.93	12/11/2025		A		125,000(1)		12/11/2025(1)	12/11/2035	Common Stock	125,000	$0	125,000(1)	D

Explanation of Responses:

1. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Alan Dunton	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oragenics (OGEN) report in this filing?

Oragenics reported that director Alan Dunton received an award of 125,000 options to purchase shares of the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.

What are the key terms of the 125,000 options granted to the Oragenics (OGEN) director?

The grant consists of 125,000 non-employee director options with an exercise price of $0.93 per share, exercisable starting 12/11/2025 and expiring on 12/11/2035, with a price of $0 for the option grant itself.

When do the Oragenics (OGEN) director options vest and expire?

According to the filing, the options vest immediately and are exercisable from 12/11/2025 until their expiration on 12/11/2035.

Under what plan were the Oragenics (OGEN) director options granted?

The options were granted under Oragenics’ 2021 Equity Incentive Plan, as amended, pursuant to the company’s non-employee director compensation program.

How many derivative securities does the Oragenics (OGEN) director own after this grant?

After the reported transaction, the director beneficially owns 125,000 derivative securities (options) directly.

What type of security underlies the options granted by Oragenics (OGEN)?

The options are a Non-Employee Director Option (Right to Buy), each relating to Oragenics’ common stock, with 125,000 shares underlying the derivative security.